Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake.
Identifieur interne : 003D51 ( Main/Exploration ); précédent : 003D50; suivant : 003D52Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake.
Auteurs : RBID : pubmed:9662589English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Carcinoma, Papillary (metabolism), Carcinoma, Papillary (radionuclide imaging), False Negative Reactions, False Positive Reactions, Female, Humans, Indium Radioisotopes (diagnostic use), Iodine (metabolism), Iodine Radioisotopes (diagnostic use), Male, Middle Aged, Prospective Studies, Radiopharmaceuticals (diagnostic use), Receptors, Somatostatin (drug effects), Receptors, Somatostatin (metabolism), Recurrence, Somatostatin (analogs & derivatives), Somatostatin (diagnostic use), Thyroglobulin (metabolism), Thyroid Neoplasms (metabolism), Thyroid Neoplasms (radionuclide imaging), Tomography, X-Ray Computed.
- MESH :
- chemical , analogs & derivatives : Somatostatin.
- chemical , diagnostic use : Indium Radioisotopes, Iodine Radioisotopes, Radiopharmaceuticals, Somatostatin.
- chemical , drug effects : Receptors, Somatostatin.
- metabolism : Carcinoma, Papillary, Iodine, Receptors, Somatostatin, Thyroglobulin, Thyroid Neoplasms.
- radionuclide imaging : Carcinoma, Papillary, Thyroid Neoplasms.
- Adult, Aged, Aged, 80 and over, False Negative Reactions, False Positive Reactions, Female, Humans, Male, Middle Aged, Prospective Studies, Recurrence, Tomography, X-Ray Computed.
Abstract
We conducted a prospective evaluation of somatostatin receptor scintigraphy (SRS) for the diagnosis of recurrent vesicular or papillary thyroid carcinoma in 16 patients with no detectable iodine uptake. SRS was performed 1, 4 and 24 h after intravenous injection of 137-200 MBq of indium-111 pentetreotide. Results were interpreted in terms of assumed presence of tumoral tissue: there were three true-positives (19%), one false-positive (6%) and 12 false-negatives (75%). The three true-positive patients had multiple lesions visible on computerized tomography. SRS was negative in all patients with a high thyroglobulin level alone. In addition, we analyzed the consequences of interpretative criteria and somatostatin receptor expression variability for SRS positivity as well as the risk of false-positives. We conclude that when iodine uptake cannot be demonstrated in patients with suspected recurrence of differentiated thyroid carcinoma, SRS would not appear to contribute to diagnosis, and that interpretative criteria commonly used for tumours with a high receptor density may be too restrictive for tumours with a low receptor density.
PubMed: 9662589
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake.</title><author><name sortKey="Garin, E" uniqKey="Garin E">E Garin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine, CRLCC Eugène Marquis, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, CRLCC Eugène Marquis, Rennes</wicri:regionArea><placeName><region type="région">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Devillers, A" uniqKey="Devillers A">A Devillers</name></author><author><name sortKey="Le Cloirec, J" uniqKey="Le Cloirec J">J Le Cloirec</name></author><author><name sortKey="Bernard, A M" uniqKey="Bernard A">A M Bernard</name></author><author><name sortKey="Lescouarc H, J" uniqKey="Lescouarc H J">J Lescouarc'h</name></author><author><name sortKey="Herry, J Y" uniqKey="Herry J">J Y Herry</name></author><author><name sortKey="Reubi, J C" uniqKey="Reubi J">J C Reubi</name></author><author><name sortKey="Bourguet, P" uniqKey="Bourguet P">P Bourguet</name></author></titleStmt><publicationStmt><date when="1998">1998</date><idno type="RBID">pubmed:9662589</idno><idno type="pmid">9662589</idno><idno type="wicri:Area/Main/Corpus">004091</idno><idno type="wicri:Area/Main/Curation">004091</idno><idno type="wicri:Area/Main/Exploration">003D51</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Carcinoma, Papillary (metabolism)</term><term>Carcinoma, Papillary (radionuclide imaging)</term><term>False Negative Reactions</term><term>False Positive Reactions</term><term>Female</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Iodine (metabolism)</term><term>Iodine Radioisotopes (diagnostic use)</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Receptors, Somatostatin (drug effects)</term><term>Receptors, Somatostatin (metabolism)</term><term>Recurrence</term><term>Somatostatin (analogs & derivatives)</term><term>Somatostatin (diagnostic use)</term><term>Thyroglobulin (metabolism)</term><term>Thyroid Neoplasms (metabolism)</term><term>Thyroid Neoplasms (radionuclide imaging)</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term><term>Iodine Radioisotopes</term><term>Radiopharmaceuticals</term><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Carcinoma, Papillary</term><term>Iodine</term><term>Receptors, Somatostatin</term><term>Thyroglobulin</term><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Carcinoma, Papillary</term><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>False Negative Reactions</term><term>False Positive Reactions</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Recurrence</term><term>Tomography, X-Ray Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We conducted a prospective evaluation of somatostatin receptor scintigraphy (SRS) for the diagnosis of recurrent vesicular or papillary thyroid carcinoma in 16 patients with no detectable iodine uptake. SRS was performed 1, 4 and 24 h after intravenous injection of 137-200 MBq of indium-111 pentetreotide. Results were interpreted in terms of assumed presence of tumoral tissue: there were three true-positives (19%), one false-positive (6%) and 12 false-negatives (75%). The three true-positive patients had multiple lesions visible on computerized tomography. SRS was negative in all patients with a high thyroglobulin level alone. In addition, we analyzed the consequences of interpretative criteria and somatostatin receptor expression variability for SRS positivity as well as the risk of false-positives. We conclude that when iodine uptake cannot be demonstrated in patients with suspected recurrence of differentiated thyroid carcinoma, SRS would not appear to contribute to diagnosis, and that interpretative criteria commonly used for tumours with a high receptor density may be too restrictive for tumours with a low receptor density.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9662589</PMID><DateCreated><Year>1998</Year><Month>09</Month><Day>11</Day></DateCreated><DateCompleted><Year>1998</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0340-6997</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>7</Issue><PubDate><Year>1998</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine</Title><ISOAbbreviation>Eur J Nucl Med</ISOAbbreviation></Journal><ArticleTitle>Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake.</ArticleTitle><Pagination><MedlinePgn>687-94</MedlinePgn></Pagination><Abstract><AbstractText>We conducted a prospective evaluation of somatostatin receptor scintigraphy (SRS) for the diagnosis of recurrent vesicular or papillary thyroid carcinoma in 16 patients with no detectable iodine uptake. SRS was performed 1, 4 and 24 h after intravenous injection of 137-200 MBq of indium-111 pentetreotide. Results were interpreted in terms of assumed presence of tumoral tissue: there were three true-positives (19%), one false-positive (6%) and 12 false-negatives (75%). The three true-positive patients had multiple lesions visible on computerized tomography. SRS was negative in all patients with a high thyroglobulin level alone. In addition, we analyzed the consequences of interpretative criteria and somatostatin receptor expression variability for SRS positivity as well as the risk of false-positives. We conclude that when iodine uptake cannot be demonstrated in patients with suspected recurrence of differentiated thyroid carcinoma, SRS would not appear to contribute to diagnosis, and that interpretative criteria commonly used for tumours with a high receptor density may be too restrictive for tumours with a low receptor density.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garin</LastName><ForeName>E</ForeName><Initials>E</Initials><Affiliation>Department of Nuclear Medicine, CRLCC Eugène Marquis, Rennes, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Devillers</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Le Cloirec</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bernard</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Lescouarc'h</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Herry</LastName><ForeName>J Y</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Reubi</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Bourguet</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>GERMANY</Country><MedlineTA>Eur J Nucl Med</MedlineTA><NlmUniqueID>7606882</NlmUniqueID><ISSNLinking>0340-6997</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>138661-02-6</RegistryNumber><NameOfSubstance>pentetreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance>Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9010-34-8</RegistryNumber><NameOfSubstance>Thyroglobulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9679TC07X4</RegistryNumber><NameOfSubstance>Iodine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma, Papillary</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">False Negative Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">False Positive Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Iodine</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Iodine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">drug effects</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Thyroglobulin</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Thyroid Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>7</Month><Day>15</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>7</Month><Day>15</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9662589</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D51 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003D51 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:9662589
|texte= Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9662589" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |